(Bloomberg) Rodman & Renshaw reiterates outperform recommendation on EpiCept after the company unveiled a study at the ASH conference. The target price is $ 2, corresponding to 13:72 crowns, implying a significant upside to Wednesday's closing price of SEK 3:09.
According to a sector analysis dated December 8.
EpiCept presented results from a meta-analysis of Ceplene with interleukin-2 (IL-2), a study that was part of the company's filing for Ceplene. Using two statistical models, researchers have found that Ceplene and IL-2 has an advantage over the standard treatment and IL-2.
Of note is that this conclusion is robust with respect to modeling assumptions, writes Rodman & Renshaw.
Rodman & Renshaw concluded that the observed leukemia-free survival of Ceplene and IL-2 over IL-2 and standard treatment is clinically relevant and should generate interest in immunotherapy as a means of maintaining the regression and prevent relapse in AML patients.